Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
Mette Deleuran, Danielle Marcoux, Marjolein S. De Bruin-Weller, Alan D. Irvine, Eulalia Baselga, Kangmo Ahn, Ana Paula Castro, Ashish Bansal, Jingdong Chao, Gaëlle Bégo-Le-Bagousse, Ana B. Rossi
DOI: 10.2340/00015555-3848
Abstract
Abstract is missing (Short communication)
Significance
Supplementary content
Comments
